💊 दवाएँ A-Z 🧬 लक्ष्य 🛠 उपकरण 📚 मार्गदर्शिकाएँ
सभी दवाएँ दवा वर्ग चिकित्सीय क्षेत्र दुष्प्रभाव
मार्गदर्शिकाएँ शब्दकोश समयरेखा
तुलनाएँ दवाओं की यात्राएँ दवा परिवार
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Vanzacaftor

CHEMBL5314934 Phase 4 अनुमोदित Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
617.8 g/mol
LogP
5.7
Phase
4

Vanzacaftor is a CFTR corrector that aids in the folding and trafficking of mutant cystic fibrosis transmembrane conductance regulator (CFTR) protein to the cell surface, used in combination with other CFTR modulators (tezacaftor and deutivacaftor) to treat cystic fibrosis. It targets multiple CFTR processing defects to increase the quantity and function of CFTR at the cell surface in patients with eligible mutations. It represents the next generation of CFTR corrector therapy.

आणविक भार

617.8000 g/mol

LogP

5.70

TPSA

140.00 Ų

लिपिंस्की RO5

अनुत्तीर्ण

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D संरचना

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
CC1(C)C[C@@H]2CCCNc3cccc(n3)S(=O)(=O)NC(=O)c3ccc(-n4ccc(OCCC5C6(CC6)C56CC6)n4)nc3N1C2

                

                

                
                

                    
InChI

                    
InChI=1S/C32H39N7O4S/c1-30(2)19-21-5-4-16-33-24-6-3-7-27(34-24)44(41,42)37-29(40)22-8-9-25(35-28(22)38(30)20-21)39-17-10-26(36-39)43-18-11-23-31(12-13-31)32(23)14-15-32/h3,6-10,17,21,23H,4-5,11-16,18-20H2,1-2H3,(H,33,34)(H,37,40)/t21-/m0/s1

                

                

                

                    
                    

                        
Molecular Formula

                        
C32H39N7O4S

                    

                    
                    

                        
HBD / HBA

                        
2 / 9

                    

                    
                    

                        
घूर्णनीय बंधन

                        
5

                    

                    
                    
                    

                        
भारी परमाणु

                        
44

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
अक्सर पूछे जाने वाले प्रश्न

                

                    
                    

                        
                        

                            
Vanzacaftor is a CFTR corrector that aids in the folding and trafficking of mutant cystic fibrosis transmembrane conductance regulator (CFTR) protein to the cell surface, used in combination with other CFTR modulators (tezacaftor and deutivacaftor) to treat cystic fibrosis. It targets multiple CFTR processing defects to increase the quantity and function of CFTR at the cell surface in patients with eligible mutations. It represents the next generation of CFTR corrector therapy.

                        

                    

                    

                    

                    

                    

                    

                        
                        

                            
Yes, Vanzacaftor is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL5314934.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 139399801.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.




        


        
        
    


    



    
चिकित्सा अस्वीकरण

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.